cytokines, TNFa (TNF), BAFF (TNFSF13B) and APRIL (TNFSF13) elaborated from BMSCs as well as OCs, and that PIM2 acts as an anti-apoptotic mediator in MM cells (Asano et al, 2011) . Importantly, PIM2 was found to be up-regulated in BMSCs as well in MM and plays a critical role in the suppression of osteoblastogenesis as an intracellular mediator downstream of osteoblastogenesis inhibitors in MM, including IL3, IL7, TNF-a, TGF-b (TGFB1) and activin A . Furthermore, PIM2 is induced in osteoclastic cells during their osteoclastogenesis by RANK ligand, and acts as a critical mediator of osteoclastogenesis in MM . Therefore, PIM2 plays a pivotal role in tumour progression and bone destruction and loss in MM, and PIM2 inhibition may become an important therapeutic strategy targeting the MM cell-bone marrow interaction. Indeed, tumour reduction and bone restoration have been demonstrated in MM animal models with the PIM inhibitor (Z)-5-(4-propoxybenzylidene)thiazolidine-2,4-dione, named SMI-16a (Xia et al, 2009) , suggesting the therapeutic impact of thiazolidine-2,4-dione-family compounds with PIM inhibiting activity on MM .
MM cells and OCs mutually interact with each other to enhance MM tumour growth while developing osteoclastic bone lesions (Abe et al, 2004 (Abe et al, , 2006 Yaccoby et al, 2004 Yaccoby et al, , 2008 Ge et al, 2006) . The MM-OC interactions in bone lesions in MM appear to create a highly acidic milieu due to protons released by OCs and lactate by proliferating glycolytic MM cells Amachi et al, 2016) . Acidic microenvironments are generally accepted to confer drug resistance and immune evasion capability in cancers (Kato et al, 2013) . We recently reported that bendamustine reduces PIM2 expression to impair MM cell viability preferentially in acidic conditions . These observations suggest that PIM2 may play a critical role in MM cell survival in the acidic conditions created in MM bone lesions. Although bone lesions confer drug resistance in MM cells, the role of PIM2 in the growth and survival of MM cells, as well as their drug resistance in acidic bone lesions in MM is largely unknown.
In the present study, we therefore aimed to clarify the therapeutic impact of the thiazolidine-2,4-dione-family compounds SMI-16a and SMI-4a (Xia et al, 2009 ) on MM cells and their progenitors in acidic conditions and on the ATPbinding cassette (ABC) transporter breast cancer resistance protein (BCRP)-expressing drug-resistant MM cells. We demonstrate here that these thiazolidine-2,4-dione-family compounds directly impair MM cell survival, preferentially in acidic conditions, and suppress BCRP function to restore drug sensitivity in MM cells. Interestingly, these compounds substantially reduced PIM2 protein levels in MM cells, preferentially in acidic conditions, in contrast to other types of PIM inhibitors, including AZD1208, CX-6258 and PIM447. In addition, SMI-16a was suggested to have the ability to impair MM progenitors with self-renewal capacity. Although the proteasome inhibitors bortezomib and carfilzomib accumulated intact PIM2 protein in MM cells through blocking its ubiquitination-independent proteasomal degradation, SMI-16a mitigated the PIM2 protein increase and cooperatively enhanced anti-MM effects with the proteasome inhibitors. These data suggest that SMI-16a and SMI-4a may become an interesting anti-MM option and warrant further study on their combination with proteasome inhibitors.
Materials and methods

Reagents
The following reagents were purchased from the indicated manufacturers: recombinant human (rh) IL6 from PeproTech EC (London, UK); rabbit anti-PIM1 antibody from Abcam (Cambridge, UK); rabbit anti-PIM2 antibody, horseradish-peroxidase (HRP)-conjugated goat anti-rabbit IgG, HRP-conjugated goat anti-mouse IgG and bortezomib from Cell Signaling Technology (Beverly, MA, USA); mouse antib-actin antibody and puromycin from Sigma (St Louis, MO, USA); anti-puromycin antibody from Kerafast, Inc (Boston, MA); SMI-16a and SMI-4a from Calbiochem (Darmstadt, Germany); AZD1208 and pomalidomide from Tronto Research Chemicals (Tronto, Canada); CX6258 from Cayman Chemical Company (Ann Arbor, MI, USA); PIM447 from BOC Sciences (Shirley, NY, USA); Cycloheximide from Nacalai Tesque (Kyoto, Japan), carfilzomib from ChemieTek (Indianapolis, IN, USA); mouse anti-human BCRP from Millipore (Temecula, CA, USA); mouse monoclonal anti-human multidrug-resistance-associated protein-1 (MRP1) and rabbit polyclonal anti-MCL1 antibodies and lenalidomide from Santa Cruz Biotechnology (Santa Cruz, CA, USA); fluorescein isothiocyanate (FITC)-labelled rabbit anti-mouse IgG from Zymed Laboratories (San Francisco, CA, USA); and phycoerythrin (PE)-labelled mouse anti-P-glycoprotein antibody and PE-mouse IgG from BD Bioscience (San Jose, CA, USA).
Cells and cultures
The human MM cell lines, RPMI8226, KMS-11 and U266 were obtained from American Type Culture Collection (ATCC) (Rockville, MD, USA). The MM cell lines INA-6 and MM.1S were kindly provided by Dr. Renate Burger (University of Kiel, Kiel, Germany) and Dr. Steven Rosen (Northwestern University, Chicago, IL, USA), respectively. TSPC-1 and OPC MM cell lines were established in our laboratory (Abe et al, 2002) . MM cells were cultured in RPMI 1640 medium supplemented with 5% fetal bovine serum, 2 mmol/l L-glutamine (Sigma), 100 u/ml penicillin G and 100 lg/ml streptomycin (Sigma). The pH levels in culture media were adjusted by adding lactic acid (Wako, Osaka, Japan). Bone marrow mononuclear cells were isolated from fresh bone marrow aspirates of patients with myeloma and primary CD138 + MM cells were further sorted using CD138 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) as described previously (Abe et al, 2002; Kitazoe et al, 2009 ). All procedures involving human specimens were performed with written informed consent according to the Declaration of Helsinki and using a protocol approved by the Institutional Review Board for human protection. 
Cell viability assays
Western blot analysis
Whole cell lysate was lysed in radioimmunoprecipitate assay (RIPA) buffer, and nuclear extract was lysed by NE-PER nuclear and cytoplasmic extraction reagent kit (Thermo Fisher Scientific, Rockford, IL, USA). These lysates were supplemented with 1 mmol/l phenylmethylsulfonyl fluoride and protease inhibitor cocktail solution (Sigma). Cell lysates and conditioned media were subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis on a 10% gel and blotted onto polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). After blocking with 5% non-fat dry milk, the membranes were incubated with primary antibodies overnight at 4°C, followed by washing and addition of a HRP-conjugated secondary antibody for 1 h. The protein bands were visualized with the Enhanced Chemiluminescence Plus Western Blotting Detection System (Amersham Biosciences, Piscataway, NJ, USA).
Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted from cells using TRIZOL reagent (Gibco BRL, Rockville, MD, USA 
Flow cytometry
Cells were incubated in 100 ll of phosphate-buffered saline (PBS) with 2% human c-globulin (Japan Blood Products Organization, Tokyo, Japan), and stained with PE-labelled mouse monoclonal anti-P-glycoprotein antibody, mouse monoclonal anti-BCRP or anti-MRP1 antibody, followed by FITC-labelled rabbit anti-mouse IgG antibody as described above. Samples were then washed and analysed by flow cytometry using an EPICS Profile cytofluorometer (Coulter Electronics, Hialeah, FL, USA). Apoptosis was evaluated by staining the cells with an annexin V-FITC and propidium iodide (PI) labelling kit (MEBCYTO Apoptosis Kit; MBL, Nagano, Japan) according to the manufacturer's instructions.
Drug accumulation and efflux assay
Drug accumulation and efflux were analysed as described previously (Abe et al, 2004) . Cells were incubated for 30 min with 100 ng/ml mitoxantrone, then washed prior to analysis of intracellular fluorescence levels by flow cytometry (accumulation phase, AP). For determining drug efflux levels, the cells were further incubated for 6 h in the presence or absence of thiazolidine-2,4-dione compounds, and intracellular fluorescence levels were analysed (efflux phase, EP).
Side population (SP) analysis
SP fractions were analysed as described previously (Ikegame et al, 2012; Harada et al, 2013) . Cells were incubated with 5 lg/ml Hoechst 33342 (Invitrogen) for 90 min at 37°C in the presence or absence of 100 lmol/l verapamil or 50 lmol/ l SMI16a. After washing, the cells were resuspended in icecold PBS supplemented with 1 lg/ml PI to detect dead cells. Hoechst 33342 was excited with an ultraviolet (UV) laser at 350 nm, and the SP fractions were analysed by flow cytometry (EPICS ALTRA HyperSort, Beckman & Coulter) with 450 nm (Hoechst blue) and 675 nm (Hoechst red) filters.
Colony formation assays
Colony formation assays were performed as described previously (Ikegame et al, 2012; Harada et al, 2013) . Cells were cultured in triplicate in 35-mm dishes containing H4034 methylcellulose medium (Stem Cell Technologies, Vancouver, BC, Canada) with 30% fetal bovine serum, 100 u/ml penicillin G and 100 lg/ml streptomycin. After culturing for 2 weeks, colonies were visualized and counted under an Olympus BX50 microscope equipped with an UMPlanFI 40X/0Á75 objective lens (Olympus, Tokyo, Japan). Images were recorded with an Olympus SC35 CCD camera and Viewfinder Lite Software (Pixera, Los Gatos, CA, USA).
Assessment of in vivo tumourigenic capacity
All animal studies were conducted in accordance with the principles and procedures approved by the University of Tokushima Institutional Review Board (toku-dobutsu 14092). MM mouse models were well established and constantly reproduced by the intra-tibial inoculation of mouse 5TGM1 MM cells to ICR nu/nu mice (CLEA Japan, Tokyo, Japan) at 4-6 weeks old, as previously described (D'Souza et al, 2011; Hiasa et al, 2015; Teramachi et al, 2016) . Therefore, we used this model to determine in vivo tumourigenic capacity. We cultured mouse 5TGM1 MM cells for 24 h in the presence or absence of 50 lmol/l SMI-16a, then the cells were washed and viable cell numbers were counted. The remaining living cells (2 9 10 5 cells) were directly inoculated to the tibia of ICR nu/nu mice. To estimate tumour growth, mouse IgG 2b protein levels in mouse sera were measured using the Mouse IgG 2b ELISA Quantitation Set (Bethyl Laboratories, Inc., Montgomery, TX, USA). Tumour sizes were measured over time after detecting palpable tumours, and the tumour volume was calculated using the formula: ab 2 p/6, where a = the longest diameter and b = the shortest diameter (Ikegame et al, 2012) .
Statistical analysis
Data are represented as means AE standard deviations unless specified otherwise. Significance was determined by a oneway analysis of variance (ANOVA) with Scheffe's post hoc tests. The minimal level of significance was P = 0Á05.
Results
The thiazolidine-2,4-dione-family compounds SMI-16a and SMI-4a induce MM cell death preferentially in acidic conditions
We first examined the expression of PIM1 and PIM2 at the protein level in MM cells. All MM cell lines, except IL6-dependent MM cell lines, INA-6, OPC and TSPC-1, clearly expressed PIM2 at baseline, whereas PIM1 expression was found only in RPMI8226 and OPC ( Fig 1A) . In cocultures with BMSCs, PIM2 was substantially up-regulated in all MM cell lines, including the above IL6-dependent ones, suggesting PIM2 overexpression in MM cells in the bone marrow. Therefore, PIM2 appears to be a predominant PIM isoform overexpressed in MM cells, as previously reported (Lu et al, 2013) .
Given that tumour acidity is known to confer drug resistance and that MM creates acidic bone lesions, we next looked at the effects of the thiazolidine-2,4-dione-family compounds, SMI-16a and SMI-4a, on MM cell viability at different pH values, including 7Á4, 6Á8 and 6Á4. Both compounds dose-dependently induced cell death in RPMI8226, KMS11 and INA-6 MM cell lines (Fig 1B) . Their cytotoxic activity was augmented as ambient pH values were lowered. The induction of apoptosis was confirmed with annexin V and PI dual staining in RPMI8226 and INA-6 cells (Figure S1) . We previously demonstrated that treatment with SMI-16a reduced the expression of the BCL family member Mcl-1 (MCL1) (Asano et al, 2011) . However, phosphorylation of BAD and the levels of other apoptosis-related factors including Bcl-xL (BCL2L1), Bcl2 (BCL2) and Bim (BCL2L11) showed no appreciable change in MM cells upon treatment with SMI-16a. Treatment with SMI-4a as well as SMI-16a reduced the expression of MCL1 in MM cells, which was further enhanced in acidic conditions (Figure S2) . We also examined the cytotoxic assay with other commercially available PIM inhibitors. AZD1208 (Dakin et al, 2012; Keeton et al, 2014; Harada et al, 2015) is another member of the thiazolidine-2,4-dione-family compounds; and CX-6258 (Haddach et al, 2012) and PIM447 (Peters et al, 2016) are structurally different types of PIM inhibitors. AZD1208, CX-6258 and PIM447 also induced dose-dependent MM cell death at pH 7Á4 (Fig 1C) . However, the cytotoxic activity of these compounds against MM cells was not increased in acidic conditions; of note, anti-MM effects of CX-6258 or PIM447 were rather blunted as pH values in culture media were lowered (Fig 1C) . Therefore, augmentation of anti-MM effects in acidic conditions appears to be unique to these thiazolidine-2,4-dione-family compounds, which may allow them to target MM cells in acidic bone lesions.
SMI-16a and SMI-4a reduce PIM2 protein levels in MM cells
PIM kinases are autophosphorylated immediately after being synthesized in cells to become constitutively active; therefore, PIM2 activity is reflected by its protein levels (Warfel & Kraft, 2015) . As PIM2 protein has been demonstrated to be rapidly degraded by a proteasome in a ubiquitination-independent manner (Adam et al, 2015) , PIM2 activity appears to be largely determined by the balance of PIM2 protein production and degradation in cells. Therefore, we next investigated whether SMI-16a and SMI-4a affect PIM2 protein levels in MM cells. Although they are kinase inhibitors, both SMI-16a and SMI-4a dose-dependently reduced PIM2 protein levels in MM cells at 24 h (Fig 2A) . However, MM cell PIM2 mRNA expression was not affected after exposure to SMI-16a or SMI-4a at pH 7Á4, 6Á8 and 6Á4 (Fig 2B) . Interestingly, both compounds were able to further reduce PIM2 protein levels in MM cells in acidic conditions, which correlated well with their anti-MM activity. Although PIM2 protein levels were robustly increased in MM cells in cocultures with BMSCs, SMI-16a and SMI-4a were both able to mitigate the upregulation of PIM2 protein levels in MM cells by BMSCs (Fig 2C) .
Although AZD1208, CX-6258 and PIM447 exerted the cytotoxic activities against MM cells, these compounds did not reduce PIM2 protein levels in RPMI8226 MM cells cultured alone or with BMSCs at the concentrations adequate to induce MM cell death (Fig 2C) . These results demonstrate that the thiazolidine-2,4-dione-family compounds SMI-16a and SMI-4a uniquely reduce PIM2 protein levels preferentially in acidic conditions, which may contribute to the augmentation of their cytotoxic actions against MM cells. 
SMI-16a and SMI-4a did not affect PIM2 protein degradation
To dissect the mechanisms of PIM2 reduction, we first confirmed the effects of PIM inhibitors other than the thiazolidine-2,4-dione-family compounds SMI-16a and SMI-4a on PIM2 mRNA expression in MM cells. Similar to SMI-16a and SMI-4a, AZD1208, CX-6258 and PIM447 did not affect PIM2 mRNA expression at the concentrations that were able to impair MM cell viability (Fig 3A) . These data suggest that PIM inhibition itself does not affect PIM2 mRNA transcription, but that SMI-16a and SMI-4a uniquely and intriguingly reduced PIM2 levels in MM cells at protein levels. As PIM2 is subject to rapid degradation by proteasomes, we looked at the effects of SMI-16a and SMI-4a on post-translational degradation of PIM2 protein in MM cells upon treatment with cycloheximide, an inhibitor of translation. As previously demonstrated in the other types of cells (Adam et al, 2015) , PIM2 protein levels were rapidly degraded in MM cells over time in the presence of cycloheximide; simultaneous treatment with SMI-16a or SMI-4a did not noticeably affect the reduction of PIM2 protein (Fig 3B) , indicating PIM2 protein reduction independent of its protein degradation.
Therefore, it is plausible that SMI-16a and SMI-4a may reduce PIM2 synthesis at translational levels. We previously reported that SMI-16a inhibited the phosphorylation of 4EBP1 to block the initiation of translation (Asano et al, 2011) . To further clarify the mechanism of the PIM2 protein reduction, we therefore investigated the effects of SMI-16a and SMI-4a on translation in MM cells using puromycin incorporation. Puromycin incorporation in neosynthesized proteins directly reflects the rate of mRNA translation (Schmidt et al, 2009) . SMI-16a and SMI-4a dose-dependently reduced the puromycin incorporation in MM cells (Fig 3C) , suggesting suppression of translation. Although PIM2 protein is quickly degraded in cells (Adam et al, 2015) , transient global suppression of translation by SMI-16a and SMI-4a may decrease PIM2 protein synthesis to cause the PIM2 protein reduction in MM cells.
Drug retention in MM cells by SMI-16a
Drug-resistant cancer cells increase their expression of ABC transporters, including P-glycoprotein (ABCB1), BCRP (ABCG2) and MRP-1 (ABCC1), which function as efflux transporters dependent on energy from the hydrolysis of ATP for a variety of chemotherapeutic drugs (Allen et al, 2000; Doyle & Ross, 2003; Dean et al, 2005; Dean, 2009; Fletcher et al, 2010) PIM kinases have been shown to be involved in the expression and activation of drug efflux transporters (Isaac et al, 2011) . PIM1 phosphorylates BCRP, and thereby promotes its multimerization with its stable membrane expression, leading to drug resistance (Xie et al, 2008) . As drug-resistant MM cells are known to aberrantly express BCRP (Zhou et al, 2001 (Zhou et al, , 2002 , we hypothesized that PIM2 overexpressed in MM cells may mediate BCRP function. To test this hypothesis, we next examined the effects of SMI-16a on intracellular retention of mitoxantrone in MM cells. Mitoxantrone is a substrate of BCRP and expelled by BCRP. Mitoxantrone emits auto-fluorescence, and its retention in MM cells can be estimated by flow cytometry. RPMI8226 cells aberrantly express BCRP on their surfaces; but it is marginally expressed on U266 cells (Fig 4A) . After passive incorporation of mitoxantrone into these cells, intracellular drug accumulation was shown as an 'accumulation phase (AP)' (Fig 4B) . The cells were then washed and incubated in media without mitoxantrone. The intracellular drug levels decreased at 6 h to the levels indicated as the 'efflux phase (EP)'. Treatment with SMI-16a increased the drug retention levels in these cells. The drug retention by SMI-16a was more prominent in BCRP-expressing RPMI8226 cells (Fig 4B) . However, although PIM2 was upregulated in MM cells in cocultures with BMSCs, SMI-16a was able to similarly restore the drug retention in the MM cells in the coculture settings. SMI-16a-induced drug retention tended to be increased in MM cells in acidic conditions. These results suggest that SMI-16a is able to restore drug retention in MM cells, preferentially in BCRP-expressing MM cells.
SMI-16a restores Dox's anti-MM effects in acidic conditions
Doxorubicin (Dox) is clinically utilized as an anti-MM agent, and a substrate of BCRP. We next examined whether the blockade of BCRP function by SMI-16a is able to enhance the cytotoxic effects of Dox against BCRP-expressing RPMI8226 cells. Dox dose-dependently induced MM cell death at pH 7Á4 (Fig 4C) . In contrast to SMI-16a, which preferentially induced MM cell death in acidic conditions (Fig 1B) , the cytotoxic activity of Dox against RPMI8226 cells was blunted at pH 6Á8 (Fig 4C) . However, simultaneous addition of SMI-16a instead restored and enhanced the cytotoxic effects of Dox in the acidic conditions. The restoration of anti-MM activity of Dox in acidic conditions in combination with SMI-16a is suggested to be at least partly due to the blockade of BCRP function by SMI-16a. exhibited SP fractions as previously reported (Jakubikova et al, 2011; Ikegame et al, 2012; Hanson et al, 2015) ( Fig 5A) . The sizes of SP fractions were substantially decreased in both MM cells upon treatment with SMI-16a for 2 days at pH 7Á4. Interestingly, exposure to SMI-16a at pH 6Á8 still further reduced the percent distributions of the SP fractions within the remaining living cells in these MM cell lines, suggesting a critical role of PIM2 in maintaining SP fractions, especially in acidic conditions.
SMI-16a reduces the sizes of SP fractions in MM cells
SMI-16a abolishes clonogenic and in vivo tumourigenic capacity of MM cells SP cells have also been reported as a drug resistant fraction in many cancers, and are considered to contain cancer stem cells (Bonnet & Dick, 1997; Challen & Little, 2006; Ho et al, 2007; Li et al, 2007; Ricci-Vitiani et al, 2007) . Treatment with SMI-16a substantially minimized the sizes of SP fractions in RPMI8226 and KMS11 cells (Fig 5A) . Given that SP fractions contain MM progenitors or MM initiating cells, there is a possibility that SMI-16a is able to target MM progenitors with stemness. To clarify the effects of SMI-16a on the clonogenic potential of MM cells, we examined colony formation of MM cells. RPMI8226 cells were pre-treated for 24 h with or without SMI-16a at pH 7Á4 or pH 6Á8, and then their capacity for colony formation was estimated, using methylcellulose assays. Spontaneous colony formation of RPMI8226 cells was substantially reduced when RPMI8226 cells were pre-treated with SMI-16a at 7Á4 as well as pH 6Á8 (Fig 5B) . We previously reported that SMI-16a efficaciously suppressed MM tumour growth and bone destruction in mouse models bearing murine 5TGM1 MM cells (Hiasa (Fig 5A and B) , it is plausible that SMI-16a can impair the self-renewal capacity of MM cells. To further investigate the effects of SMI-16a on the self-renewal capacity of MM cells, we next conducted experiments for in vivo tumourigenic capacity of MM cells. We cultured 5TGM1 cells for 24 h in the presence or absence of SMI-16a. After pre-treatment, the cells were washed and the remaining living cells were collected and counted. The same numbers of viable MM cells with or without the pre-treatment with SMI-16a were inoculated into the tibiae of SCID mice. Without the SMI-16a pre-treatment, the MM cells rapidly formed tumours expanding outside of the tibiae (Fig 5C) , and all the mice died within a month after confirming tumour growth at day 21. However, 5TGM1 cells pre-treated with SMI-16a were not able to form tumours ( Fig 5C) ; and 5TGM1 cell-derived IgG 2b was not detected in the mouse sera (Fig 5D) . No tumour was detected even at 3 months in the mice receiving the SMI-16a-pretreated MM cells, suggesting targeting of clonogenic MM cells. These results suggest that SMI-16a effectively impairs MM cells, including their clonogenic fractions.
SMI-16a mitigates PIM2 accumulation in MM cells by proteasome inhibitors
Consistent with the previous observation with proteasomal degradation of PIM2 protein (Adam et al, 2015; Warfel & Kraft, 2015) , treatment with the proteasome inhibitors bortezomib and carfizomib dose-dependently increased PIM2 protein levels in KMS11 cells at 6 h without increasing their PIM2 mRNA expression (Fig 6A) . However, the immunomodulatory drugs lenelidomide and pomalidomide did not increase PIM2 protein levels. Addition of SMI-16a reduced the PIM2 protein levels increased in RPMI8226 and KMS11 cells by bortezomib or carfizomib (Fig 6B) . IL6 The remaining living cells (2 9 10 5 cells) were directly inoculated to the tibia of ICR nu/nu mice (SMI-16a-treated and control cells to 4 and 3 mice, respectively). Tumour sizes were measured over time after detecting palpable tumours (C). *indicates the significant difference from the controls (P < 0Á05). To further estimate tumour growth, mouse sera were taken at 21 days after the inoculation, and 5TGM1 MM cell-derived mouse IgG 2b protein levels in the mouse sera were measured (D). Data were expressed as mean AE SD. *P < 0Á05. [Colour figure can be viewed at wileyonlinelibrary.com] markedly upregulated PIM2 protein levels in these MM cells; bortezomib still further increased their PIM2 protein levels in the presence of IL6. SMI-16a was able to reduce PIM2 protein levels in RPMI8226 and KMS11 cells upon treatment with bortezomib, even in the presence of IL6.
Carfilzomib is a second-generation proteasome inhibitor, which irreversibly inhibits proteasome actions and can induce cytotoxic activity against MM cells resistant to botezomib. Carfilzomib and SMI-16a cooperatively enhanced cytotoxicity against RPMI8226 cells (Fig 6C) . KMS11 cells appeared to be resistant to carfilzomib; however, addition of SMI-16a was able to reduce their viability. These data suggest that SMI-16a enhances the cytotoxic activity of carfilzomib, which may be partly due to inhibition of the action of PIM2 accumulated through proteasome inhibition.
Discussion
The present study demonstrates that the thiazolidine-2,4-dione-family compounds SMI-16a and SMI-4a impair MM cell survival, preferentially in acidic conditions, while substantially reducing PIM2 protein levels. Acidic enhancement of their anti-MM actions and PIM2 protein reduction in MM cells appears to be unique to these compounds and is not observed in other types of PIM inhibitors, including AZD1208, CX-6258 and PIM447. The pKa of SMI-16a and SMI-4a and the zwitterionic character of AZD1208 can affect the difference in their activity against MM cells at the different pH values, although they are all thiazolidine-2,4-dionefamily compounds. At acidic pH values, an amino group of AZD1208 should be protonated, rendering it hard to pass through a cell membrane via simple diffusion. On the other hand, SMI-4a and SMI-16a, with no amino group, are insensitive to pH changes in solution. The basic character of CX-6258 and PIM447, structurally different PIM inhibitors, may cause the difference in the cytotoxic activity in acidic conditions and the effects on PIM2 levels in MM cells. The reduction by SMI-16a and SMI-4a of PIM2 protein levels in MM cells may contribute to their marked efficacy along with their immediate kinase inhibition. Although these compounds did Bortezomib (Bor) and carfilzomib (Carfil) were added at the indicated concentrations. Lenalidomide (LEN) and pomalidomide (POM) were added at 1 lmol/l. After culturing for 6 h, PIM2 protein and PIM2 mRNA levels were examined in the MM cells by Western blot analysis and by reverse transcription polymerase chain reaction (RT-PCR), respectively. b-actin was used as a loading control for the immunoblotting. GAPDH was used as an internal control for the RT-PCR. (B) RPMI8226 and KMS11 cells were cultured for 24 h in the presence or absence of 10 ng/ml IL6. Bortezomib (Bor) and carfilzomib (Carfil) were added at the indicated concentrations. SMI-16a was added at 50 lmol/l as indicated. PIM2 protein levels were examined in the MM cells by Western blot analysis. (C) RPMI8226 and KMS11 cells were cultured in triplicate for 48 h and their viability was determined by WST-8 assay. Carfilzomib (Carfil) was added at 10 and 20 lmol/l for RPMI8226 and KMS11 cells, respectively. SMI-16a was added at 25 lmol/l. Cell viability was determined by a WST-8 assay after culturing for 2 days. Results are expressed as an optical density (means AE SD).
Anti-myeloma Activity by Thiazolidine-2,4-dione Compounds ª 2018 John Wiley & Sons Ltd not affect transcription or degradation of PIM2, precise mechanisms of PIM2 protein reduction by these compounds still remain to be clarified in MM cells. In addition, compared to the 50% inhibitory concentration values for PIM kinase inhibition of these compounds (several to 150 nmol/l) previously described by Xia et al (2009) and the insertions of the compounds used in the present study, in vitro cytotoxic activity required relatively higher concentrations (several to more than 10 lmol/l); therefore, off-target effects may also affect their potencies of cytotoxic activity. Chemotherapeutic drugs are generally accepted to have limited effects on clonogenic MM cells or SP cells because of their detoxification potential. SMI-16a was able to suppress BCRP drug efflux function to recover drug susceptibility in MM cells. Importantly, SMI-16a was able to target SP fractions with high BCRP function in MM cells, and impair their clonogenic capacity, indicating the merit of this compound. As BCRP is predominantly expressed in drug-resistant MM cells and their progenitors, the up-regulation of PIM2 appears to involve drug efflux in MM cells to reduce the efficacy of drug treatment. Sensitization of MM cells to chemotherapeutic agents by PIM inhibition warrants further study on combinatory treatment of anti-MM agents, such as doxorubicin and carfilzomib, with PIM inhibitors.
Bortezomib and carfizomib were found to accumulate a large amount of PIM2 protein in MM cells. As PIM2 protein is subject to ubiquitination-independent proteasomal degradation, PIM2 protein accumulated in MM cells by the proteasome inhibitors appears to be intact. PIM2 is a critical survival factor in MM cells and PIM2 accumulation may therefore compromise the anti-MM effects of proteasome inhibitors. Therefore, the present results warrant further study on combinatory treatment of proteasome inhibitors with agents with PIM inhibitory and reducing activity, such as SMI-16a and SMI-4a.
